Hostname: page-component-7c8c6479df-ws8qp Total loading time: 0 Render date: 2024-03-28T19:24:43.820Z Has data issue: false hasContentIssue false

A study of polio vaccination in infancy: excretion following challenge with live virus by children given killed or living poliovaccine

Published online by Cambridge University Press:  15 May 2009

J. L. Henry
Affiliation:
London County Council
E. S. Jaikaran
Affiliation:
London County Council
Joan R. Davies
Affiliation:
Public Health Laboratory Service, County Hall, London, S.E. 1
A. J. H. Tomlinson
Affiliation:
Public Health Laboratory Service, County Hall, London, S.E. 1
P. J. Mason
Affiliation:
Glaxo Research Ltd, Sefion Park, Stoke Poges, Bucks.
Joan M. Barnes
Affiliation:
Glaxo Research Ltd, Sefion Park, Stoke Poges, Bucks.
A. J. Beale
Affiliation:
Glaxo Research Ltd, Sefion Park, Stoke Poges, Bucks.
Rights & Permissions [Opens in a new window]

Extract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Quadruple vaccine containing 75 D antigen units of killed type 1 poliovirus was given to children at ages 2, 3 and 4 months followed by a booster dose at 15 months.

The serological response to the primary course was difficult to assess owing to maternal antibody. Antibody titres to the type 1 component after the booster dose were very satisfactory and about 10 times higher than those observed in a similar group of children given attenuated vaccine. Response to the poliovirus types 2 and 3 in the quadruple vaccine was less satisfactory.

Graded doses of attenuated poliovirus type 1 were fed to the children 2 months after the primary course and 1 month after the booster dose. Children who had received no poliovaccine and children immunized with attenuated vaccine were included for comparison.

Immunization with killed vaccine did not greatly affect the size of the minimal infecting dose of live virus but reduced both the duration of the subsequent infection and the titre of virus in the faeces.

The epidemiological significance of these findings is discussed.

Type
Research Article
Copyright
Copyright © Cambridge University Press 1966

References

REFERENCES

Beale, A. J. & Ungar, J. (1962). Potency and stability of combined pertussis, diphtheria, tetanus and poliomyelitis (quadruple) vaccine. Lancet, ii, 805.CrossRefGoogle Scholar
Butler, M. R., Barr, M. & Glenny, A. T. (1954). Immunization of young babies against diphtheria. Br. med. J. i, 476.CrossRefGoogle Scholar
Dane, D. S. (1964). The future of inactivated poliomyelitis vaccines. Proc. R. Soc. Med. 57, 462.Google ScholarPubMed
Dane, D. S., Dick, G. W. A., Simpson, D. I. H., Bbiggs, E. M., McAlister, J., Nelson, R. & Field, C. M. B. (1962). New quadruple vaccine. Lancet, i, 939.CrossRefGoogle Scholar
Durand, D. P. (1962). Virus neutralization test in a capillary tube. Science, 138, 448.CrossRefGoogle Scholar
Galbraith, N. S. (1964). Proc. Xth Symposium Europ. Ass. Poliomyelitis and Allied Diseases.Warsaw.Google Scholar
Gard, S. (1964). Proc. Xth Symposium Europ. Ass. Poliomyelitis and Allied Diseases.Warsaw.Google Scholar
Lyng, J. & Bentzon, M. W. (1963). International standards for anti-poliovirus sera types 1, 2 and 3. Bull. Wld Hlth Org. 29, 711.Google Scholar
Mair, H. J. & Tobin, J. O'H. (1960). Some observations on the use of secondary monkey kidney cell cultures for the routine diagnosis of virus diseases. Mon. Bull. Minist. Hlth, 19, 49.Google ScholarPubMed
Oblandini, O., Sass-Kobtsak, A. & Ebbs, J. H. (1955). Serum gamma globulin levels in normal infants. Pediatrics, Springfield, 16, 575.Google Scholar
Perkins, F. T. & Evans, D. G. (1959). British standard poliomyelitis antisera types 1, 2 and 3. Br. med. J. i, 1549.CrossRefGoogle Scholar
Perkins, F. T., Yetts, R. & Gaisfoed, W. (1958). Serological response of infants to poliomyelitis vaccine. Br. med. J. ii, 68.CrossRefGoogle Scholar
Perkins, F. T., Yetts, R. & Gaisfoed, W. (1959). Response of infants to a third dose of poliomyelitis vaccine given 10 to 12 months after primary immunization. Br. med. J. i, 680.CrossRefGoogle Scholar
Report (1961). Trial of living attenuated poliovirus vaccine. A report of the Public Health Laboratory Service to the Poliomyelitis Vaccines Committee of the Medical Research Council. Br. med. J. ii, 1037.Google Scholar
Report (1965). The excretion of type 1 poliovirus after challenge following primary immunization with quadruple, Salk and Sabin vaccines. A study by the Public Health Laboratory Service. Mon. Bull. Minist. Hlth, 24, 365.Google Scholar